The short version of peptide backbone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-22 and is reviewed periodically as new material appears.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
An earlier multicenter analysis of the randomized IDE study reported similar findings, with improved patient-reported outcomes relative to fusion. These improvements included greater reductions in disability as measured by the Oswestry Disability Index (ODI), a standard scale used to assess limitations in daily activities due to back pain. A separate long-term follow-up has shown that TOPS preserves near-normal motion and may reduce the risk of adjacent segment degeneration.
== Other uses == BrightBus, a former British vehicle body manufacturer and school bus operator that previously traded as MASS Engineering Manab Adhikar Sangram Samiti, a human rights NGO in Assam (India) Marc and Eva Stern Math and Science School (Stern MASS) Maritime Autonomous Surface Ship, An autonomous cargo ship Maß (pronounced "mass"), a German word describing the amount of beer in a regulation mug, also used for the mug itself Mass (mass spectrometry), a chemical analysis technique Mass (object), a high-density object Mawson Analytical Spectrometry Services, services offered at the University of Adelaide, Australia Tumor, or mass, a neoplasm that is enlarged
Over the course of their career, the band's sound has also been described as alternative metal, sludge metal, alternative rock, doom metal, and hard rock. Furthermore, the band have also incorporated styles including blues rock, folk rock, progressive rock, funk metal and jangle pop into their music. Regarding the band's constant categorization by the media, Cantrell stated: When we first came out we were metal. Then we started being called alternative metal. Then grunge came out and then we were hard rock. And now, since we've started doing this again I've seen us listed as: hard rock, alternative, alternative metal and just straight metal. I walked into an HMV the other day to check out the placement and see what's on and they've got us relegated back into the metal section. Right back where we started! Drummer Sean Kinney rejects the grunge label, stating in a 2013 interview "I mean, before we first came out there was no grunge, they hadn't invented that word. Before they invented the word grunge we were alternative rock and alternative metal and metal and rock, and we didn't give a shit whatever, we were a rock and roll band!" According to Mike Inez, they were always the metal stepchildren of the Seattle scene.
=== BOC (1968-2006) === BOC Group's purchase of Edwards in 1968 was followed by international expansion, particularly into Asia, and investment at the Crawley, Eastbourne, Shoreham and Burgess Hill sites. In 1984, Edwards developed and patented the first practical high vacuum dry (no-oil) pump. The design was taken up by the fast-growing semiconductor manufacturing market. In 1992, Edwards purchased Electrotech Ltd's semiconductor manufacturing exhaust gas management systems. It was based in Nailsea before moving to Clevedon, UK to add to Edwards' semiconductor manufacturing environmental abatement technology. Four years later in 1996, new facilities in Burgess Hill are inaugurated. In 1997, BOC merged its electronics gases business with Edwards as BOC Edwards. In the same year, the company purchased Systems Chemistry Inc, a supplier of management systems for ultrapure chemicals used in semiconductor manufacturing, from Submicron Systems Corp of Allentown (USA). It became Edwards' chemical management division. Allentown, USA. It became Edwards' chemical management division. In 1999, Edwards acquired the Minneapolis-based division of FSI International Inc, for US$38 million. This was followed by the purchase of the Hick Hargreaves vacuum ejector and deaerator units; Wilhelm Klein GmbH; Stokes piston pump operations, and Hibon Inc for £12.8 million from Smiths Group. In 2002, they purchased Seiko Industry's turbomolecular pump manufacturing business for £70 million.
"True alkaloids" contain nitrogen in the heterocycle and originate from amino acids. Their characteristic examples are atropine, nicotine, and morphine. This group also includes some alkaloids that besides the nitrogen heterocycle contain terpene (e.g., evonine) or peptide fragments (e.g. ergotamine). The piperidine alkaloids coniine and coniceine may be regarded as true alkaloids (rather than pseudoalkaloids: see below) although they do not originate from amino acids. "Protoalkaloids", which contain nitrogen (but not the nitrogen heterocycle) and also originate from amino acids. Examples include mescaline, adrenaline and ephedrine. Polyamine alkaloids – derivatives of putrescine, spermidine, and spermine. Peptide and cyclopeptide alkaloids. Pseudoalkaloids – alkaloid-like compounds that do not originate from amino acids. This group includes terpene-like and steroid-like alkaloids, as well as purine-like alkaloids such as caffeine, theobromine, theacrine and theophylline. Some authors classify ephedrine and cathinone as pseudoalkaloids. Those originate from the amino acid phenylalanine, but acquire their nitrogen atom not from the amino acid but through transamination. Some alkaloids do not have the carbon skeleton characteristic of their group. So, galanthamine and homoaporphines do not contain isoquinoline fragment, but are, in general, attributed to isoquinoline alkaloids. Main classes of monomeric alkaloids are listed in the table below:
Sources: en.wikipedia.org
Following the release of his mixtape Hologram Panda with producer Dame Grease, Riff Raff told MTV that his upcoming Mad Decent second studio album would be titled Riff Raff, The Neon Icon, later shortened to Neon Icon. In February 2013 he told Complex that his second studio album is due out some time during the third quarter of 2013. On June 25, 2013, he released a single titled "Dolce & Gabbana", produced by DJ Carnage as the first single from Neon Icon, however two days later he announced that the song wouldn't be included on the album. He was also featured on Far East Movement's single "The Illest" around the same time. Then on July 12, 2013, he released another non album single titled "Mr. Popular", and four days later released the music video for the song. In August 2013, Riff Raff announced that he would be releasing a collaboration album with Action Bronson titled Galaxy Gladiators in 2014. On November 26, 2013, he released the first official single for Neon Icon titled "How To Be the Man" and produced by DJ Mustard. That same month, Riff Raff told Rolling Stone in an interview that leading up to the album's release he would release various "left-over" tracks from the album's recording sessions These notably included the Boi-1da produced "Real Boyz", featuring rappers OJ da Juiceman and Cap 1, as well as "Suckas Askin' Questions" with Lil Debbie and "Shoulda Won a Grammy" with Action Bronson. In March 2014, prior to the album's release, Rolling Stone included the album on their list of "27 Must-Hear Albums of 2014".
=== Brand names === Dutasteride is sold primarily under the brand name Avodart, but also in combination with tamsulosin under the brand names Combodart, Duodart, and Jalyn. Dutasteride is also available in India in combination with alfuzosin under the brand names Alfusin-D and Dutalfa.
=== Tumor suppressor === Loss-of-heterozygosity (LOH) of the 7q22.1 chromosomal region, where CUX1 resides, was reported in 8–22% of various cancer, and in close to 50% in therapy-associated leukemias. As no inactivating mutations were found in the remaining allele, the notion that CUX1 could be the tumor suppressor gene on 7q22.1 was dismissed for some time. However, refined mapping in leiomyomas and myeloid leukemias eventually pointed to CUX1 as the sole tumor suppressor gene in this region. These genetic data suggest that CUX1 may be a haploinsufficient tumor suppressor gene. In addition to LOH events, large scale DNA sequencing identified inactivating point mutations in 1–5% of cancers where both alleles are present. There is no tumor case where both CUX1 allele are inactivated. While the biochemical activities of CUX1 that explain its role in tumor maintenance and progression have been well defined, the biochemical functions of CUX1 involved in tumor suppression have yet to be firmly established. Two mechanisms have been proposed. One study reported that CUX1 functions as a transcriptional activator of PIK3IP1, a gene that codes for the phosphoinositide-3-kinase interacting protein 1 (PIK3IP1), a direct inhibitor of the PI3K p110 catalytic subunit. CUX1 knockdown caused a decrease in PIK3IP1 expression that was associated with an increase in PI3K signaling and AKT signaling. A separate study, however, argued that CUX1 is itself a target of AKT signaling.
=== Disability and death === Due to distance, Hodgkin decided not to attend the 1987 Congress of the International Union of Crystallography in Australia. However, despite increasing frailty, she astounded close friends and family by going to Beijing for the 1993 Congress, where she was welcomed by all. She died in July 1994 after a stroke, at her husband's home in the village of Ilmington, near Shipston-on-Stour, Warwickshire.
On 16 September 1994, the 82nd Airborne Division joined Operation Uphold Democracy. The 82nd was scheduled to make combat parachute jumps into Pegasus Drop Zone and PAPIAP Drop Zone (Port-au-Prince Airport), to help oust Raoul Cédras and to restore Jean-Bertrand Aristide to the presidency. At the same time, former US president Jimmy Carter and former chairman of the Joint Chiefs of Staff Colin Powell were negotiating with Cédras to restore Aristide to power, the 82nd's first wave was in the air, with paratroopers waiting at Green Ramp to air-land in Haïti once the airfields there had been seized. When the Haitian military verified from sources outside Pope Air Force Base that the 82nd was on the way, Cédras stepped down, averting the invasion. Former vice president Al Gore later travelled to Fort Bragg to personally thank the paratroopers of the 82nd for their actions, noting in a speech on 19 September 1994, that the 82nd's reputation was enough to change Cédras' mind:
Sources: en.wikipedia.org
Historians have noted that Chinese scholars wrote these studies instead of "books of prescriptions or advice manuals." In their historical and environmental understanding, no two illnesses were alike, so the healing strategies of the practitioner were unique every time to the specific diagnosis of the patient. Medical case studies existed throughout Chinese history, but "individually authored and published case history" was a prominent creation of the Ming dynasty. An example of such case studies would be the literati physician, Cheng Congzhou, collection of 93 cases published in 1644.
, where K is the Kardashev type of a civilization and W is the amount of power it uses, in watts. Thus, a Type 1.1 civilization would be defined by a power of 1017 watts, while a Type 2.3 civilization would be able to harness 1029 watts. Moreover, the above formula could be used to extrapolate beyond Kardashev's original types. For example, a Type 0 civilization, not defined by Kardashev, would control about 1 MW of power (equivalent to having around 100 campfires burning at any given time); on Earth, the emergence of Type 0 civilizations is roughly concurrent with the rise of civilization in a general sense. Sagan estimated that, according to this revised scale, 1970s humanity would be Type 0.7 (about 10 terawatts), equivalent to 0.16% of the power available on Earth. This level is characterized, according to him, by the ability to self-destruct, which he calls "technological adolescence". In 2021, the total world energy consumption was 595.15 exajoules (165,319 TWh), equivalent to an average power consumption of 18.87 TW or a Kardashev rating of 0.73. Sagan also suggests that, for completeness, an alphabetical scale should be added to indicate the level of social development, expressed in the amount of information available to the civilization. Thus, a Class A civilization would be based on 106 bits of information (less than any recorded human culture), a Class B on 107 bits, a Class C on 108 bits, and so on. Humanity in 1973 would belong to the "0.7 H" class.
Biological tissue has little inherent contrast in either the light or electron microscope. Staining is employed to give both contrast to the tissue as well as highlighting particular features of interest. When the stain is used to target a specific chemical component of the tissue (and not the general structure), the term histochemistry is used.
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy in tablet form, and molly in crystal form, is an entactogen with stimulant and minor psychedelic properties. MDMA was first synthesized in 1912 by Merck chemist Anton Köllisch. It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s. MDMA is commonly used by attendees of dance parties, raves, and electronic dance music festivals. Tablets sold as ecstasy may be mixed with other substances such as ephedrine, amphetamine, and methamphetamine. The lethal risk from one dose of MDMA is estimated to be from 1 death in 20,000 instances to 1 death in 50,000 instances. The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours. Short-term adverse effects include bruxism, blurred vision, sweating, and tachycardia, and extended use can also lead to addiction, amnesia, memory disorders, paranoia, and insomnia. Deaths have been reported due to increased body temperature and dehydration. MDMA acts primarily by increasing the release of the neurotransmitters serotonin, dopamine, and norepinephrine in parts of the brain. It belongs to the substituted amphetamine classes of drugs. MDMA is structurally similar to mescaline (a psychedelic), methamphetamine (a stimulant), as well as endogenous monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.